Pharmacogenetic variability of tuberculosis biomarkers in native and mestizo Peruvian populations

IF 2.9 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Luis Jaramillo‐Valverde, Kelly S. Levano, David D. Tarazona, Silvia Capristano, Cesar Sanchez, Julio A. Poterico, Eduardo Tarazona‐Santos, Heinner Guio
{"title":"Pharmacogenetic variability of tuberculosis biomarkers in native and mestizo Peruvian populations","authors":"Luis Jaramillo‐Valverde, Kelly S. Levano, David D. Tarazona, Silvia Capristano, Cesar Sanchez, Julio A. Poterico, Eduardo Tarazona‐Santos, Heinner Guio","doi":"10.1002/prp2.1179","DOIUrl":null,"url":null,"abstract":"In Peru, 29 292 people were diagnosed with tuberculosis in 2022. Although tuberculosis treatments are effective, 3.4%–13% are associated with significant adverse drug reactions, with drug‐induced liver injury (DILI) considered the most predominant. Among the first‐line antituberculosis drugs, isoniazid is the main drug responsible for the appearance of DILI. In liver, isoniazid (INH) is metabolized by N‐acetyltransferase‐2 (<jats:italic>NAT2</jats:italic>) and cytochrome P450 2E1 (<jats:italic>CYP2E1</jats:italic>). Limited information exists on genetic risk factors associated with the presence of DILI to antituberculosis drugs in Latin America, and even less is known about these factors in the native and mestizo Peruvian population. The aim of this study was to determine the prevalence of <jats:italic>NAT2</jats:italic> and <jats:italic>CYP2E1</jats:italic> genotypes in native and mestizo population. An analytical cross‐sectional analysis was performed using genetic data from mestizo population in Lima and native participants from south of Peru. <jats:italic>NAT2</jats:italic> metabolizer was determined as fast, intermediate and slow, and <jats:italic>CYP2E1</jats:italic> genotypes were classified as c1/c1, c1/c2 and c2/c2, from molecular tests and bioinformatic analyses. Of the 472 participants, 36 and 6 <jats:italic>NAT2</jats:italic> haplotypes were identified in the mestizo and native population, respectively. In mestizo population, the most frequent <jats:italic>NAT2</jats:italic>*5B and <jats:italic>NAT2</jats:italic>*7B haplotypes were associated with DILI risk; while in natives, <jats:italic>NAT2</jats:italic>*5G and <jats:italic>NAT2</jats:italic>*13A haplotypes were associated with decreased risk of DILI. For <jats:italic>CYP2E1</jats:italic>, c1/c1 and c1/c2 genotypes are the most frequent in natives and mestizos, respectively. The linkage disequilibrium of <jats:italic>NAT2</jats:italic> single nucleotide polymorphisms (SNPs) was estimated, detecting a block between all SNPs natives. In addition, a block between rs1801280 and rs1799929 for <jats:italic>NAT2</jats:italic> was detected in mestizos. Despite the limitations of a secondary study, it was possible to report associations between <jats:italic>NAT2</jats:italic> and <jats:italic>CYP2E</jats:italic> alleles with Peruvian native and mestizo by prevalence ratios. The results of this study will help the development of new therapeutic strategies for a Tuberculosis efficient control between populations.","PeriodicalId":19948,"journal":{"name":"Pharmacology Research & Perspectives","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology Research & Perspectives","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/prp2.1179","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

In Peru, 29 292 people were diagnosed with tuberculosis in 2022. Although tuberculosis treatments are effective, 3.4%–13% are associated with significant adverse drug reactions, with drug‐induced liver injury (DILI) considered the most predominant. Among the first‐line antituberculosis drugs, isoniazid is the main drug responsible for the appearance of DILI. In liver, isoniazid (INH) is metabolized by N‐acetyltransferase‐2 (NAT2) and cytochrome P450 2E1 (CYP2E1). Limited information exists on genetic risk factors associated with the presence of DILI to antituberculosis drugs in Latin America, and even less is known about these factors in the native and mestizo Peruvian population. The aim of this study was to determine the prevalence of NAT2 and CYP2E1 genotypes in native and mestizo population. An analytical cross‐sectional analysis was performed using genetic data from mestizo population in Lima and native participants from south of Peru. NAT2 metabolizer was determined as fast, intermediate and slow, and CYP2E1 genotypes were classified as c1/c1, c1/c2 and c2/c2, from molecular tests and bioinformatic analyses. Of the 472 participants, 36 and 6 NAT2 haplotypes were identified in the mestizo and native population, respectively. In mestizo population, the most frequent NAT2*5B and NAT2*7B haplotypes were associated with DILI risk; while in natives, NAT2*5G and NAT2*13A haplotypes were associated with decreased risk of DILI. For CYP2E1, c1/c1 and c1/c2 genotypes are the most frequent in natives and mestizos, respectively. The linkage disequilibrium of NAT2 single nucleotide polymorphisms (SNPs) was estimated, detecting a block between all SNPs natives. In addition, a block between rs1801280 and rs1799929 for NAT2 was detected in mestizos. Despite the limitations of a secondary study, it was possible to report associations between NAT2 and CYP2E alleles with Peruvian native and mestizo by prevalence ratios. The results of this study will help the development of new therapeutic strategies for a Tuberculosis efficient control between populations.
秘鲁原住民和混血儿结核病生物标志物的药物基因变异性
2022 年,秘鲁共有 29 292 人被诊断患有结核病。虽然结核病治疗有效,但 3.4%-13%的患者会出现严重的药物不良反应,其中最主要的是药物性肝损伤(DILI)。在一线抗结核药物中,异烟肼是导致 DILI 出现的主要药物。在肝脏中,异烟肼(INH)通过 N-乙酰转移酶-2(NAT2)和细胞色素 P450 2E1 (CYP2E1)进行代谢。在拉丁美洲,与抗结核药物所致 DILI 相关的遗传风险因素的信息非常有限,而秘鲁本地人和混血儿对这些因素的了解就更少了。本研究旨在确定 NAT2 和 CYP2E1 基因型在本地人和混血儿中的流行率。研究利用利马混血人群和秘鲁南部土著参与者的基因数据进行了横断面分析。通过分子检测和生物信息学分析,NAT2 代谢分为快速、中速和慢速,CYP2E1 基因型分为 c1/c1、c1/c2 和 c2/c2。在 472 名参与者中,梅斯蒂索人和本地人分别发现了 36 种和 6 种 NAT2 单倍型。在混血儿中,最常见的 NAT2*5B 和 NAT2*7B 单倍型与 DILI 风险有关;而在本地人中,NAT2*5G 和 NAT2*13A 单倍型与 DILI 风险降低有关。就 CYP2E1 而言,c1/c1 和 c1/c2 基因型分别在本地人和混血人中最为常见。对 NAT2 单核苷酸多态性(SNPs)的连锁不平衡进行了估计,发现所有 SNPs 在本地人之间存在阻断。此外,在混血儿中检测到了 NAT2 的 rs1801280 和 rs1799929 之间的阻滞。尽管二次研究有其局限性,但仍能通过患病率比值报告 NAT2 和 CYP2E 等位基因与秘鲁本地人和混血儿之间的关联。这项研究的结果将有助于制定新的治疗策略,有效控制不同人群之间的结核病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives Pharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics
CiteScore
5.30
自引率
3.80%
发文量
120
审稿时长
20 weeks
期刊介绍: PR&P is jointly published by the American Society for Pharmacology and Experimental Therapeutics (ASPET), the British Pharmacological Society (BPS), and Wiley. PR&P is a bi-monthly open access journal that publishes a range of article types, including: target validation (preclinical papers that show a hypothesis is incorrect or papers on drugs that have failed in early clinical development); drug discovery reviews (strategy, hypotheses, and data resulting in a successful therapeutic drug); frontiers in translational medicine (drug and target validation for an unmet therapeutic need); pharmacological hypotheses (reviews that are oriented to inform a novel hypothesis); and replication studies (work that refutes key findings [failed replication] and work that validates key findings). PR&P publishes papers submitted directly to the journal and those referred from the journals of ASPET and the BPS
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信